POSTOPERATIVE RADIOTHERAPY OF NON-SMALL CELL LUNG CANCER
https://doi.org/10.18027/2224-5057-2014-3-91-96
Abstract
Despite advances in the treatment of cancer, lung cancer still takes the first place in the structure of mortality from malignant neoplasms. Non-small cell lung cancer (NSCLC) is about 85% of all cases of lung cancer. The standard treatment of early NSCLC is surgical approach. Because of the large proportion of patients who continue to suffer from local recurrence after radical surgery and adjuvant chemotherapy it is necessary to reconsider the role of postoperative radiation therapy (PORT) in NSCLC patients. The results of the meta-analysis of using of PORT, published in 1998, were disappointing. Adjuvant radiotherapy for pN0 pN1 increased the risk of death by 21%, reducing the 2-year overall survival by 7%. At stage III and pN2 patients results were controversial: PORT slightly improved local control, but had no effect on overall survival. Along with criticism of this meta-analysis, the literature provides evidence from randomized studies confirming benefits of the using of PORT. In this review article potential misconceptions about the "dangers" of PORT as well as critical issues for determining the indications for PORT in NSCLC are considered. Despite advances in the treatment of lung cancer it still takes first place in the structure of mortality from cancer in many countries, including Russian Federation. Non-small cell lung cancer (NSCLC) is about 85% of all cases of lung cancer. Patients with I, II and IIIA stage of NSCLC are considered potentially resectable with 5-year survival after radical surgery ~ 60-90%, 30- 70% and 10-30%, respectively. The standard treatment of early NSCLC is surgical approach. Adjuvant therapy is not recommended for patients with stage I of NSCLC after R0-resection in accordance with the guidelines NCCNV.3.2014. However, the 5-year survival rate for patients with stage I of NSCLC according to different studies ranges from 50% to 90% with relapse within 5 years after surgery, which stimulates the researches for an effective adjuvant therapy for the last few decades.
About the Authors
Fagim F. Mufazalov
Республиканский клинический онкологический диспансер, Республики Башкортостан, г. Уфа
Russian Federation
Russian Federation
Nailya S. Sharipova
Республиканский клинический онкологический диспансер, Республики Башкортостан, г. Уфа
Russian Federation
Russian Federation
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
2. Состояние онкологической помощи населению России в 2013 годупод редакцией А. Д. Каприна, В. В. Старинского Г. В. Петровой; М2014.
3. Mountain CF. Revisions in the International System for staging lung cancer.Chest. 1997;111 (6):1710–7.
4. Bakira M, Fraser S, RoutledgeIs T et al. Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement? InteractCardiovascThoracSurg 2011; 13: 303–310.
5. Koike T, Yamato Y, Yoshiya K et al. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J ThoracCardiovascSurg 2003;125: 924–928.
6. Maeda R, Yoshida J, Ishii G et al. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the 7th edition TNM classification. Chest 2011; 140: 1494–1502.
7. Manser R, Wright G, Hart D, Byrnes G, Campbell DA. Surgery for early stagenon-small cell lung cancer. Cochrane Database Syst Rev 2005: CD004699.
8. Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol. 2010; Suppl 7: vii 196–8.
9. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J ThoracOncol 2007;2:694–705.
10. Thomas WS, Joseph L, Ronald BP, Valerie WR. General thoracic surgery, vol.6. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1653.
11. Non Small Cell Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899–909.
12. International Adjuvant Lung cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med 2004;350:351–60.
13. Strauss GM, Herndon 2nd JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J ClinOncol 2008;26:5043–51.
14. Winton TL, Livingston R, Johnson D, et al. For the National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators Vinorelbine plus cisplatinvs observation in resected non-small cell lung cancer Intergroup. New Engl J Med 2005;352:2589–97.
15. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719–27.
16. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267–77.
17. PORT Meta-analysis Trialists Group. Post-operative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257–63.
18. Burdett S, Stewart LOn behalf of the PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005;47:81–3.
19. Burdett S, Rydzewska L, Tierney JF, Fisher DJ. A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell lung cancer. Lung Cancer 2013;80:350–2.
20. Bekelman JE, Rosenzweig KE, Bach PB, et al. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J RadiatOncolBiolPhys 2006;66:492–499. [PubMed:16814952]
21. Jeffrey A. Bogart1 and Jesse N. Aronowitz2 Localized Non^Small Cell Lung Cancer: Adjuvant Radiotherapy in the Era of Effective Systemic Therapy Clin Cancer Res 2005;11 (13 Suppl) July 1, 2005
22. Philips P, RocmansP, Vanderhoef P, Van HoutteP.Postop erativeradiotherapyafterpneumonectomy: impact of modern treatment facilities. IntJRadiatOncolBiol Phys1993;27:525^9.
23. MunroAJ. What now for postoperative radiotherapy for lung cancer? Lancet1998;352:250^1.
24. Lung Cancer Study Group. Effects of post-operative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986;315:1377–81.
25. Dautzenberg B, Arriagada R, Chammard AB, etal. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 1999; 86: 265^73.
26. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase II randomized trial. RadiotherOncol 2002;62:11^9.
27. SawyerT.E., Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA nonsmall cell lung cancer according to regression tree analyses of recurrence risks. Ann ThoracSurg 1997;64:1402^8.
28. Machtay M, Lee JH, Sjrager JB, Kaiser LR, Gladstein E. Risk of death from intercurrent disease is not excessively increased by modern post-operative radiotherapy for high risk resected nonsmall cell lung carcinoma. J ClinOncol 2001;1119: 3912^7.
29. Rescigno J. Use of postoperative radiotherapy for node-positive non-small-cell lung cancer. Clin Lung Cancer 2002;4:35^44.
30. Kepka L, Bujko K, Orlowski TM, et al. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy. RadiotherOncol 2011;98:238–43.
31. Fan etal.Risk factors for locoregional recurrence in patientswith resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy Radiation Oncology 2013, 8:286
32. Koo HK, Jin SM, Lee CH et al. Factors associated with recurrence in patients with curatively resected stage I–II lung cancer. Lung Cancer 2011; 73: 222–229.
33. Luzzi L, Voltolini L, CampioneA et al. Pneumonectomyvs lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival? J CardiovascSurg (Torino) 2003; 44: 119–123.
34. Sawyer TE, Bonner JA, Gould PM et al. Factors predicting patterns of recurrence
35. Lopez J. L.et al Risk factors for local and regional recurrence in patients with resected N0–N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy Annals of Oncology 0: 1–8, 201
36. Nathan M. Mollberg et al. Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Ann ThoracSurg 2014;97:965–72
37. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan–Kettering experience with 136 patients. Ann ThoracSurg 1993;55:1365–73.
38. Andre´ F, Grunenwald D, Pignon JP, et al. Survival of patientswith resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J ClinOncol 2001;16:2981–9.
39. van Meerbeeck JP, Kramer GW, Van Schil PE, etalfor the European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst2007;99:442–50.
40. Betticher DC. Hsu Schmitz SF, Tötsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatinneoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J ClinOncol 2003;21:1752–9.
41. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J ThoracOncol 2006;1:611–21.
42. Betticher DC, Hsu Schmitz S-F, Totsch M, et alfor the Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099–106.
43. Amini A, Lou F, Correa AM, et al. Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Ann SurgOncol 2013;20:1934–40.
44. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006;30:787–92.
45. De Leyn P, Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:1–8.
46. Rami-Porta R, WittekindCGoldstraw for the International Association for the Study of Lung Cancer (IASLC) staging committee. Complete resection of lung cancer surgery: proposed definition. Lung Cancer 2005;49:25–33
47. Le Pe´choux C, Dunant A, Pignon JP, et al. Need for a new trial to evaluate adjuvant postoperative radiotherapy in nonsmallcell lung cancer patients with N2 mediastinal involvement. J ClinOncol 2007;25: e10–1.
Review
For citations:
Mufazalov F.F., Sharipova N.S. POSTOPERATIVE RADIOTHERAPY OF NON-SMALL CELL LUNG CANCER. Malignant tumours. 2014;(3):91-96. (In Russ.) https://doi.org/10.18027/2224-5057-2014-3-91-96
Views:
1225
Email this article 